This study revealed that Venetoclax can upregulate the expression of the NK cell receptor (NKG2D) and induce the expression of ligands to the corresponding protein (NKG2DL), playing a bidirectional immune regulatory role between NK and AML cells, activating the NKG2D/NKG2DL immune signaling pathway, and ultimately enhancing its antileukemic effect. This evidence concerns the gene KLRK1 and acute myeloid leukemia.